Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2003

View Archived Issues

Improved safety profile for transdermal oxybutynin vs. oral tolterodine in overactive bladder

Drotrecogin alfa (activated) in severe sepsis patients with multiple organ dysfunction

Oral RDP-58 may be effective in Crohn's disease

Nicotine metabolites may play a positive role in Alzheimer's disease

A new, orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition

GeneMax licenses Crucell's PER.C6 cell line technology

Lilly returns rhGH program rights to Emisphere

SBIR grants support anticancer drug development at Tularik

Gilead begins enrollment in phase III Viread combination trial

Phase II results for clazosentan in postsubarachnoid hemorrhage vasospasm

GTI-2040 cleared to enter NCI phase II breast cancer trial in combination with capecitabine

Arriva-ProMetic completes phase I trial of rAAT in atopic dermatitis patients

Genyous initiates clinical trials of AQC MAC test for early-stage lung cancer

Immtech completes P. vivax patient enrollment in phase IIa trial of DB-289

Phase IIb trial initiated for DB-289 in PCP

New NAALADase inhibitors in early development at Guilford

New agents for inflammatory, immune and proliferative disorders identified at Eisai

Novel PDE7B inhibitors with utility in osteoporosis therapy claimed by Bayer

Abbott researchers present new PARP inhibitors and their use in recent patent

New sodium channel blockers prepared and tested by Ortho-McNeil scientists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...